Safety and Efficacy of Imatinib Versus Interferon-α Plus... | NCT00333840

NCT00333840

Status Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
imatinib (STI571)	Experimental	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.	Drug: imatinib mesilate Drug: interferon-alpha (INF-a) Drug: cytarabine (ARA-C)
IFN-a+Ara-C	Active Comparator	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.	Drug: imatinib mesilate Drug: interferon-alpha (INF-a) Drug: cytarabine (ARA-C)

Name	Type	Description	Arm Group Labels	Other Names
imatinib mesilate	Drug	imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.	IFN-a+Ara-C imatinib (STI571)

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)	Overall survival was defined as the time between date of randomization and death due to any cause. The time was censored at last examination date for patients who were still being treated and at date of last contact for patients who discontinued treatment. Kaplan-Meier estimates of the percentage of participants at each time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.	12,24,36,48,60,72,84,96,108,120,132 and 144 months

Secondary Outcomes

Measure	Description	Time Frame
Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)	Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: progression to Accelerated Phase (AP) or Blast Crisis (BC) loss of Complete Hematological Response (CHR) loss of Major Cytogenetic Response (MCyR) confirmed loss of Major Cytogenetic Response (MCyR) unconfirmed increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) death (due to any cause when reported as primary reason for discontinuation of treatment). Kaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Eligibility Module

Name	Affiliation	Role
Novartis Pharmaceuticals	Novartis Pharmaceuticals	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Novartis Investigative Site		Birmingham	Alabama	35294	United States
Novartis Investigative Site

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
28273028	Derived	Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
23620574

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.
BG001	IFN-a + Ara-C	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (CSI151). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age Continuous

Median

Full Range

years

Title

Denominators

Categories

12 months (n = 553, 553)

Title	Measurements
	OG00098.9(98 to 100) OG00197.7(96 to 99)

24 months (n = 542, 512)

Title	Measurements
	OG000

Secondary

Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)

Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment:

progression to Accelerated Phase (AP) or Blast Crisis (BC)
loss of Complete Hematological Response (CHR)
loss of Major Cytogenetic Response (MCyR) confirmed
loss of Major Cytogenetic Response (MCyR) unconfirmed
increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC)
death (due to any cause when reported as primary reason for discontinuation of treatment).

Kaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Intent-to-treat population included all randomized participants. n = number of participants at risk at the beginning of the specific time interval

Posted

Number

Percentage of participants

12,24,36,48,60,72,84,96,108,120,132 and 144 months

ID	Title	Description
OG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.

Secondary

Percentage of Participants With Event Free Survival Events (All Randomized Participants)

Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment:

progression to Accelerated Phase (AP) or Blast Crisis (BC)
loss of Complete Hematological Response (CHR)
loss of Major Cytogenic Response (MCyR) confirmed
loss of Major Cytogenic Response (MCyR) unconfirmed
increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC)
death (due to any cause when reported as primary reason for discontinuation of treatment).

The percentage of participants with Event Free Survival events in each category was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Intent-to-treat population included all randomized participants.

Posted

Number

Percentage of participants

144 months

ID	Title	Description
OG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.
OG001	IFN-a + Ara-C

Secondary

Kaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)

Time to progression to AP/BC is defined as the time between randomization and either of the following events on treatment: death (due to CML when reported as primary reason for discontinuation of treatment) or progression to Accelerated Phase or Blast Crisis and is censored at last examination date for patients without event. No data after discontinuation of study treatment was included. The Kaplan Meier estimates of the percentage of participants with survival without progression to AP/BC at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.

Intent-to-treat population included all randomized participants. n = number of participants at risk at the beginning of the specific time interval

Posted

Number

Percentage of participants

12,24,36,48,60,72,84,96,108,120,132 and 144 months

ID	Title	Description
OG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C) in the second-line treatment period. Maximum study duration was 11.5 years.

Secondary

Percentage of Participants With Best Cytogenetic Response (First-line Treatment)

Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Philadelphia chromosome positive (Ph+) metaphases) and amount of blasts and promyelocytes in bone marrow to establish cytogenetic response.

Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= > 0 and ≤ 35 % of Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.

Intent-to-treat participants included all randomized participants.

Posted

Number

Percentage of participants

144 months

ID	Title	Description
OG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.
OG001	IFN-a + Ara-C	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.

Secondary

Percentage of Participants With Best Cytogenetic Response (Second-line Treatment)

Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Ph chromosome (Ph+) containing metaphases) and the amount of blasts and promyelocytes in bone marrow to establish cytogenetic response.

Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= > 0 and ≤ 35 % Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.

Intent-to-treat participants included all randomized participants.

Posted

Number

Percentage of participants

144 months

ID	Title	Description
OG000	Imatinib to IFN-a + Ara-C	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month.
OG001	IFN-a + Ara-C to Imatinib	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571) 400 mg orally once daily in the morning.

Secondary

Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)

A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant

Safety Population included all randomized participants who received study drug.

Posted

Number

Participants

144 months

ID	Title	Description
OG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.
OG001	IFN-a + Ara-C	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.

Secondary

Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)

Safety Population included all randomized participants who received study drug.

Posted

Number

Participants

144 months

ID	Title	Description
OG000	Imatinib to IFN-a + Ara-C	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 mu/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month in the second-line treatment period.
OG001	IFN-a + Ara-C to Imatinib	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571) 400 mg orally once daily in the morning.

Secondary

Percentage of Participants With Major Molecular Response (First-line Treatment)

Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.

Intent-to-treat population included all randomized participants.

Posted

Number

Percentage of participants

12,24,36,48,60,72,84,96,108,120,132 and 144 months

ID	Title	Description
OG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C). Maximum study duration was 11.5 years.
OG001	IFN-a + Ara-C	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.

Secondary

Percentage of Participants With Major Molecular Response (Second-line Treatment)

Intent-to-treat population included all randomized participants. No participants in the imatinib to IFN-a + Ara-C arm were available for testing.

Posted

Number

Percentage of participants

12,24,36,48,60,72,84,96,108,120,132 and 144 months

ID	Title	Description
OG000	IFN-a + Ara-C to Imatinib	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571) 400 mg orally once daily in the morning.

Units	Counts
Participants

Arm/Groups

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Imatinib (STI571)	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) and cytarabine (ARA-C) in the second-line treatment period. Maximum study duration was 11.5 years.	226	551	541	551
EG001	IFN-a + Ara-C	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.	163	533	531	533
EG002	Imatinib to IFN-a + Ara-C	In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month.	2	14	13	14
EG003	IFN-a + Ara-C to Imatinib	In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571) 400 mg orally once daily in the morning.	160	363	347	363

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Acquired Von Willebrand's disease	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG0030 affected363 at risk
Anaemia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0006 affected551 at risk EG00110 affected533 at risk EG0020 affected14 at risk EG003
Autoimmune thrombocytopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Disseminated intravascular coagulation	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Febrile neutropenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Haematotoxicity	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Haemolysis	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Haemorrhagic anaemia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Iron deficiency anaemia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Leukocytosis	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Leukopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Lymph node pain	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Lymphadenopathy	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Neutropenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Pancytopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Splenic infarction	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Splenomegaly	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Thrombocytopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG00110 affected533 at risk EG0020 affected14 at risk EG003
Thrombocytosis	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acute myocardial infarction	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Angina pectoris	Cardiac disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Angina unstable	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Aortic valve disease	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aortic valve stenosis	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Arrhythmia	Cardiac disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Arteriosclerosis coronary artery	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Atrial fibrillation	Cardiac disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Bradycardia	Cardiac disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bundle branch block left	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Cardiac arrest	Cardiac disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cardiac failure	Cardiac disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cardiac failure congestive	Cardiac disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Cardiac tamponade	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cardio-respiratory arrest	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Cardiomegaly	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cardiomyopathy	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cardiovascular disorder	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Conduction disorder	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Coronary artery disease	Cardiac disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Heart valve incompetence	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypertensive heart disease	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Ischaemic cardiomyopathy	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Left ventricular dysfunction	Cardiac disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Left ventricular failure	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Mitral valve stenosis	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Myocardial infarction	Cardiac disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0015 affected533 at risk EG0020 affected14 at risk EG003
Nodal arrhythmia	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Palpitations	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pericardial effusion	Cardiac disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pericarditis	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sick sinus syndrome	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sinus arrhythmia	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Supraventricular tachycardia	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tachycardia	Cardiac disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Torsade de pointes	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ventricular extrasystoles	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ventricular fibrillation	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Ventricular tachycardia	Cardiac disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Gene mutation	Congenital, familial and genetic disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sensory neuropathy hereditary	Congenital, familial and genetic disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Deafness	Ear and labyrinth disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Vertigo	Ear and labyrinth disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Goitre	Endocrine disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hyperparathyroidism	Endocrine disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypopituitarism	Endocrine disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hypothyroidism	Endocrine disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Blindness	Eye disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Blindness unilateral	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Conjunctival haemorrhage	Eye disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Diabetic retinopathy	Eye disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Diplopia	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Eyelid oedema	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Glaucoma	Eye disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Open angle glaucoma	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Papilloedema	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Retinal detachment	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Retinal haemorrhage	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Retinal vein thrombosis	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vision blurred	Eye disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Vitreous haemorrhage	Eye disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Abdominal discomfort	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Abdominal distension	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Abdominal mass	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Abdominal pain	Gastrointestinal disorders	15.0	Systematic Assessment	EG00012 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Abdominal pain lower	Gastrointestinal disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Abdominal tenderness	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acute abdomen	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Anal fissure	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Anal fistula	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Barrett's oesophagus	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Colitis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Constipation	Gastrointestinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Crohn's disease	Gastrointestinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Diarrhoea	Gastrointestinal disorders	15.0	Systematic Assessment	EG0009 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Diarrhoea haemorrhagic	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Diverticular perforation	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Duodenal ulcer	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Duodenitis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Dyspepsia	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Dysphagia	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Faecal vomiting	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Faecaloma	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Flatulence	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastric ulcer	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Gastritis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastritis erosive	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastritis haemorrhagic	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastrointestinal disorder	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastrointestinal haemorrhage	Gastrointestinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastrointestinal ulcer	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gingival bleeding	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gingival pain	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Haematemesis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hiatus hernia	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ileus	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Impaired gastric emptying	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Inflammatory bowel disease	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Inguinal hernia	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Intestinal haemorrhage	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Intestinal obstruction	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Intestinal perforation	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Large intestine perforation	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Mallory-Weiss syndrome	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Melaena	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Mouth haemorrhage	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Nausea	Gastrointestinal disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0018 affected533 at risk EG0020 affected14 at risk EG003
Odynophagia	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Oedematous pancreatitis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Painful defaecation	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pancreatic pseudocyst	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pancreatitis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Pancreatitis acute	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Proctalgia	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Proctitis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rectal haemorrhage	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sigmoiditis	Gastrointestinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Small intestinal obstruction	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Subileus	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tongue cyst	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vomiting	Gastrointestinal disorders	15.0	Systematic Assessment	EG00011 affected551 at risk EG0017 affected533 at risk EG0020 affected14 at risk EG003
Abasia	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Adverse drug reaction	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Asthenia	General disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Cardiac death	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Chest discomfort	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Chest pain	General disorders	15.0	Systematic Assessment	EG00014 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Chills	General disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Condition aggravated	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Crepitations	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Device malfunction	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Drug ineffective	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Drug interaction	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Drug intolerance	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Fatigue	General disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0017 affected533 at risk EG0021 affected14 at risk EG003
Gait disturbance	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
General physical health deterioration	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Generalised oedema	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Granuloma	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hernia	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hyperplasia	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hyperthermia	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Impaired healing	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Influenza like illness	General disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Malaise	General disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Mucosal atrophy	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Multi-organ failure	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Necrosis	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Non-cardiac chest pain	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Oedema peripheral	General disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Pain	General disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Performance status decreased	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Pyrexia	General disorders	15.0	Systematic Assessment	EG00019 affected551 at risk EG00120 affected533 at risk EG0021 affected14 at risk EG003
Soft tissue inflammation	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Spinal pain	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sudden cardiac death	General disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Systemic inflammatory response syndrome	General disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bile duct stone	Hepatobiliary disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Biliary tract disorder	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cholangitis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cholecystitis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0006 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cholecystitis acute	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cholelithiasis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Cytolytic hepatitis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Drug-induced liver injury	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gallbladder perforation	Hepatobiliary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Granulomatous liver disease	Hepatobiliary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatic failure	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatic function abnormal	Hepatobiliary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hepatic necrosis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatitis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatitis acute	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatomegaly	Hepatobiliary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatotoxicity	Hepatobiliary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hyperbilirubinaemia	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Jaundice	Hepatobiliary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Anaphylactic shock	Immune system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Drug hypersensitivity	Immune system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Transplant rejection	Immune system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Abscess	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Amoebiasis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Anal abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Anorectal infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Appendicitis	Infections and infestations	15.0	Systematic Assessment	EG0004 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Arthritis bacterial	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bacteraemia	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bacterial infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bone tuberculosis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bronchitis	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Bronchitis viral	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bronchopneumonia	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bronchopulmonary aspergillosis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cellulitis	Infections and infestations	15.0	Systematic Assessment	EG0006 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Clostridium difficile colitis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Diverticulitis	Infections and infestations	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ear infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Epstein-Barr virus infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Escherichia bacteraemia	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Escherichia sepsis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Escherichia urinary tract infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Folliculitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gangrene	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastritis viral	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastroenteritis	Infections and infestations	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastroenteritis norovirus	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastroenteritis rotavirus	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastroenteritis viral	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gastrointestinal infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Haemophilus infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hepatitis B	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Herpes zoster	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Incision site infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Influenza	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lobar pneumonia	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Localised infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lower respiratory tract infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lung infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Malaria	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Meningitis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Meningitis pneumococcal	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Meningoencephalitis herpetic	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Muscle abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Mycoplasma infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Necrotising fasciitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Neutropenic sepsis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Orchitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Osteomyelitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Parotitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Pelvic abscess	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Peridiverticular abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Perirectal abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pharyngitis	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pneumococcal sepsis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Pneumocystis jiroveci pneumonia	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pneumonia	Infections and infestations	15.0	Systematic Assessment	EG00012 affected551 at risk EG0017 affected533 at risk EG0020 affected14 at risk EG003
Pneumonia streptococcal	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Post procedural infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Prostate infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pseudomembranous colitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pyelonephritis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Rectal abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Respiratory tract infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Respiratory tract infection viral	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rhinitis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Salmonellosis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Salpingitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Scrotal abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Scrotal gangrene	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sepsis	Infections and infestations	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Septic shock	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Sinusitis	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Staphylococcal infection	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Streptococcal infection	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Subcutaneous abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Systemic candida	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Tonsillitis	Infections and infestations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tooth abscess	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tracheobronchitis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tuberculoma of central nervous system	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Upper respiratory tract infection	Infections and infestations	15.0	Systematic Assessment	EG0004 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Urinary tract infection	Infections and infestations	15.0	Systematic Assessment	EG0004 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Urosepsis	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Viral infection	Infections and infestations	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Viral upper respiratory tract infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vulvitis	Infections and infestations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Wound infection	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Wound infection staphylococcal	Infections and infestations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Accidental overdose	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Animal bite	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Ankle fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Arthropod bite	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Cervical vertebral fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Compression fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Concussion	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Contusion	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Exposure via father	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Facial bones fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Fall	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Femoral neck fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Femur fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Fibula fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Graft dysfunction	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Head injury	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hip fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Humerus fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Joint dislocation	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Limb injury	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lumbar vertebral fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Meniscus lesion	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Overdose	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Post procedural complication	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Post procedural haematoma	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rib fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Road traffic accident	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Skull fractured base	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Subdural haematoma	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tendon rupture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Thermal burn	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Thoracic vertebral fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tooth fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Toxicity to various agents	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Upper limb fracture	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Urethral stricture postoperative	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vascular graft occlusion	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vascular injury	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Vascular pseudoaneurysm	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Wound secretion	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Alanine aminotransferase increased	Investigations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Amylase increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aspartate aminotransferase abnormal	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aspartate aminotransferase increased	Investigations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Blast cell count increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blast cells present	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood alkaline phosphatase increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood bilirubin increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood creatine increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood creatine phosphokinase increased	Investigations	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood creatinine increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood culture positive	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood parathyroid hormone increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blood pressure increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Body temperature increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Creatinine renal clearance decreased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Echocardiogram abnormal	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Gamma-glutamyltransferase increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Haemoglobin decreased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Heart rate increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hepatic enzyme increased	Investigations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lipase increased	Investigations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Liver function test abnormal	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Multiple gated acquisition scan abnormal	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Myelocyte present	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Platelet count increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Prostatic specific antigen increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Troponin increased	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Weight decreased	Investigations	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
White blood cell count increased	Investigations	15.0	Systematic Assessment	EG0000 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Cachexia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Dehydration	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0015 affected533 at risk EG0020 affected14 at risk EG003
Diabetes mellitus	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Electrolyte imbalance	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Food intolerance	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Gout	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypercalcaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hyperglycaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Hyperkalaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypokalaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypovolaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG00111 affected533 at risk EG0021 affected14 at risk EG003
Arthritis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0016 affected533 at risk EG0020 affected14 at risk EG003
Bone disorder	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bone pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0016 affected533 at risk EG0021 affected14 at risk EG003
Compartment syndrome	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Flank pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Groin pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Inclusion body myositis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Joint swelling	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Mixed connective tissue disease	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Muscle atrophy	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Muscular weakness	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG00110 affected533 at risk EG0020 affected14 at risk EG003
Myositis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Neck mass	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Neck pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Osteitis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Osteoarthritis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Osteolysis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Osteonecrosis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Osteoporotic fracture	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0015 affected533 at risk EG0020 affected14 at risk EG003
Pain in jaw	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Polyarthritis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rheumatoid arthritis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Rotator cuff syndrome	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Spinal column stenosis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Spondylolisthesis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Systemic lupus erythematosus	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tendonitis	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acral lentiginous melanoma stage unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acute leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acute myeloid leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0006 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Benign anorectal neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bladder cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blast cell crisis	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Blast crisis in myelogenous leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0004 affected551 at risk EG0015 affected533 at risk EG0020 affected14 at risk EG003
Bone neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Brain neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Breast neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bronchioloalveolar carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Carcinoma in situ	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cervix carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Chloroma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Cholesteatoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Chronic lymphocytic leukaemia transformation	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Chronic myeloid leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Colon cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Endometrial cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Erythroleukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypergammaglobulinaemia benign monoclonal	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Laryngeal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lip and/or oral cavity cancer recurrent	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lung adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lung neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lymphoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Malignant melanoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Malignant melanoma in situ	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Metastases to adrenals	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Metastases to bone	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Metastases to large intestine	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Metastases to liver	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Metastatic neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Metastatic renal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Multiple myeloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0004 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Myelodysplastic syndrome	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Myelofibrosis	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0004 affected551 at risk EG0012 affected533 at risk EG0021 affected14 at risk EG003
Neoplasm of appendix	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Nephroblastoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Neuroendocrine tumour	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Non-Hodgkin's lymphoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Oesophageal carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pancreatic neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Paraneoplastic syndrome	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Parathyroid tumour benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Prostate cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG00011 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Prostate cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Prostatic adenoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rectal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rectal cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Renal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Renal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Signet-ring cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Small cell lung cancer stage unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Squamous cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0006 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Squamous cell carcinoma of the cervix	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Thyroid adenoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Thyroid cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Tongue neoplasm malignant stage unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Transitional cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Amyotrophic lateral sclerosis	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aphasia	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Areflexia	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ataxia	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Balance disorder	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Brain mass	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Brain oedema	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Carotid artery aneurysm	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Carotid artery occlusion	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Carotid artery stenosis	Nervous system disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Carpal tunnel syndrome	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Cerebellar syndrome	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Cerebral artery occlusion	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cerebral infarction	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cerebrovascular accident	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Cervicobrachial syndrome	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cognitive disorder	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Coma	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Complex regional pain syndrome	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Complicated migraine	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Convulsion	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Dementia	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Dementia Alzheimer's type	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Demyelination	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Diabetic neuropathy	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Disturbance in attention	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Dizziness	Nervous system disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0015 affected533 at risk EG0021 affected14 at risk EG003
Dizziness postural	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Epilepsy	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Extrapyramidal disorder	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Grand mal convulsion	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Headache	Nervous system disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Hemiparesis	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hypoxic-ischaemic encephalopathy	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Intercostal neuralgia	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Intracranial pressure increased	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ischaemic stroke	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Loss of consciousness	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Migraine	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Monoparesis	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Multiple sclerosis	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Neurological symptom	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Neurotoxicity	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Paraesthesia	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Paraplegia	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Parkinson's disease	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Peripheral sensory neuropathy	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Peroneal nerve palsy	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Piriformis syndrome	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Polyneuropathy	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Presyncope	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Radiculopathy	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Sciatica	Nervous system disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Simple partial seizures	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Somnolence	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Speech disorder	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Subarachnoid haemorrhage	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Syncope	Nervous system disorders	15.0	Systematic Assessment	EG0008 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Temporal lobe epilepsy	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Transient global amnesia	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Transient ischaemic attack	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Tremor	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
VIIth nerve paralysis	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Abortion spontaneous	Pregnancy, puerperium and perinatal conditions	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pregnancy	Pregnancy, puerperium and perinatal conditions	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aggression	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Agitation	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Anxiety	Psychiatric disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Completed suicide	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Confusional state	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Delirium	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Depression	Psychiatric disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG00115 affected533 at risk EG0020 affected14 at risk EG003
Depression suicidal	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Disorientation	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Homicidal ideation	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Mania	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Mental status changes	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Mood altered	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Paranoia	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Psychotic disorder	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Suicidal ideation	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0015 affected533 at risk EG0020 affected14 at risk EG003
Acute prerenal failure	Renal and urinary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Calculus ureteric	Renal and urinary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Calculus urethral	Renal and urinary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Dysuria	Renal and urinary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Haematuria	Renal and urinary disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Nephrolithiasis	Renal and urinary disorders	15.0	Systematic Assessment	EG0006 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Nephrotic syndrome	Renal and urinary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Oliguria	Renal and urinary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pollakiuria	Renal and urinary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Proteinuria	Renal and urinary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Renal colic	Renal and urinary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Renal failure	Renal and urinary disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Renal failure acute	Renal and urinary disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Renal failure chronic	Renal and urinary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Urethral stenosis	Renal and urinary disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Urinary tract obstruction	Renal and urinary disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Benign prostatic hyperplasia	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Breast mass	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Epididymitis	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Menorrhagia	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Metrorrhagia	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ovarian cyst	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Penis disorder	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Prostatic dysplasia	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Prostatitis	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Testicular swelling	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vaginal cyst	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Varicose veins pelvic	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acute respiratory distress syndrome	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aspiration	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Asthma	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Atelectasis	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bronchial hyperreactivity	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bronchitis chronic	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Chronic respiratory failure	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG00011 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Dyspnoea exertional	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Epistaxis	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Haemoptysis	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hiccups	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypercapnia	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hyperventilation	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypoxia	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Interstitial lung disease	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lung disorder	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Lung infiltration	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Nasal obstruction	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pharyngeal erythema	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pharyngeal stenosis	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pickwickian syndrome	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pleural effusion	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Pleurisy	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pneumonia aspiration	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pneumonitis	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pneumothorax	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Productive cough	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Pulmonary oedema	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Respiratory distress	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Respiratory failure	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Sleep apnoea syndrome	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Wheezing	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Acute febrile neutrophilic dermatosis	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Angioedema	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cutaneous vasculitis	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Dermal cyst	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Drug eruption	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Erythema multiforme	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Erythema nodosum	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hyperhidrosis	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Increased tendency to bruise	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Petechiae	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Polymorphic light eruption	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rash	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rash erythematous	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Rash maculo-papular	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Skin exfoliation	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Skin lesion	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Skin necrosis	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Stevens-Johnson syndrome	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Swelling face	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Urticaria	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Cardiac assistance device user	Social circumstances	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Disability	Social circumstances	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Miscarriage of partner	Social circumstances	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Abortion induced	Surgical and medical procedures	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Abscess drainage	Surgical and medical procedures	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Bone marrow transplant	Surgical and medical procedures	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Coronary arterial stent insertion	Surgical and medical procedures	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Stem cell transplant	Surgical and medical procedures	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aneurysm	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Aortic aneurysm	Vascular disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Aortic stenosis	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Arterial occlusive disease	Vascular disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Arteriosclerosis	Vascular disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Circulatory collapse	Vascular disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Deep vein thrombosis	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Femoral artery occlusion	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Haematoma	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Haemorrhage	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Hypertension	Vascular disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hypertensive crisis	Vascular disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Hypotension	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Iliac artery occlusion	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Iliac artery stenosis	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Infarction	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Ischaemia	Vascular disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Lymphoedema	Vascular disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Orthostatic hypotension	Vascular disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0020 affected14 at risk EG003
Peripheral arterial occlusive disease	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Peripheral vascular disorder	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Phlebitis	Vascular disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0020 affected14 at risk EG003
Varicophlebitis	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003
Vascular occlusion	Vascular disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0010 affected533 at risk EG0020 affected14 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG00064 affected551 at risk EG00158 affected533 at risk EG0020 affected14 at risk EG00337 affected363 at risk
Leukopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG00026 affected551 at risk EG00128 affected533 at risk EG0022 affected14 at risk EG003
Monocytopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Neutropenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG00058 affected551 at risk EG00168 affected533 at risk EG0021 affected14 at risk EG003
Pancytopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0014 affected533 at risk EG0022 affected14 at risk EG003
Thrombocytopenia	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG00070 affected551 at risk EG001129 affected533 at risk EG0024 affected14 at risk EG003
Thrombocytosis	Blood and lymphatic system disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0013 affected533 at risk EG0021 affected14 at risk EG003
Deafness	Ear and labyrinth disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0015 affected533 at risk EG0021 affected14 at risk EG003
Ear pain	Ear and labyrinth disorders	15.0	Systematic Assessment	EG00017 affected551 at risk EG00118 affected533 at risk EG0021 affected14 at risk EG003
Vertigo	Ear and labyrinth disorders	15.0	Systematic Assessment	EG00022 affected551 at risk EG00139 affected533 at risk EG0020 affected14 at risk EG003
Hypothyroidism	Endocrine disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG00111 affected533 at risk EG0021 affected14 at risk EG003
Conjunctivitis	Eye disorders	15.0	Systematic Assessment	EG00046 affected551 at risk EG00127 affected533 at risk EG0020 affected14 at risk EG003
Dry eye	Eye disorders	15.0	Systematic Assessment	EG00020 affected551 at risk EG00116 affected533 at risk EG0021 affected14 at risk EG003
Eye pain	Eye disorders	15.0	Systematic Assessment	EG00014 affected551 at risk EG00123 affected533 at risk EG0021 affected14 at risk EG003
Eye swelling	Eye disorders	15.0	Systematic Assessment	EG00050 affected551 at risk EG0017 affected533 at risk EG0020 affected14 at risk EG003
Eyelid oedema	Eye disorders	15.0	Systematic Assessment	EG00049 affected551 at risk EG0017 affected533 at risk EG0020 affected14 at risk EG003
Growth of eyelashes	Eye disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Lacrimation increased	Eye disorders	15.0	Systematic Assessment	EG00042 affected551 at risk EG0014 affected533 at risk EG0020 affected14 at risk EG003
Periorbital oedema	Eye disorders	15.0	Systematic Assessment	EG000165 affected551 at risk EG0016 affected533 at risk EG0020 affected14 at risk EG003
Retinal exudates	Eye disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0021 affected14 at risk EG003
Abdominal discomfort	Gastrointestinal disorders	15.0	Systematic Assessment	EG00040 affected551 at risk EG00110 affected533 at risk EG0020 affected14 at risk EG003
Abdominal pain	Gastrointestinal disorders	15.0	Systematic Assessment	EG00090 affected551 at risk EG00162 affected533 at risk EG0021 affected14 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	15.0	Systematic Assessment	EG00074 affected551 at risk EG00164 affected533 at risk EG0020 affected14 at risk EG003
Constipation	Gastrointestinal disorders	15.0	Systematic Assessment	EG00063 affected551 at risk EG00177 affected533 at risk EG0022 affected14 at risk EG003
Diarrhoea	Gastrointestinal disorders	15.0	Systematic Assessment	EG000250 affected551 at risk EG001231 affected533 at risk EG0022 affected14 at risk EG003
Dry mouth	Gastrointestinal disorders	15.0	Systematic Assessment	EG00016 affected551 at risk EG00158 affected533 at risk EG0021 affected14 at risk EG003
Dyspepsia	Gastrointestinal disorders	15.0	Systematic Assessment	EG000105 affected551 at risk EG00144 affected533 at risk EG0021 affected14 at risk EG003
Flatulence	Gastrointestinal disorders	15.0	Systematic Assessment	EG00040 affected551 at risk EG0018 affected533 at risk EG0020 affected14 at risk EG003
Gastric disorder	Gastrointestinal disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0013 affected533 at risk EG0021 affected14 at risk EG003
Gastrooesophageal reflux disease	Gastrointestinal disorders	15.0	Systematic Assessment	EG00035 affected551 at risk EG00113 affected533 at risk EG0020 affected14 at risk EG003
Gingival bleeding	Gastrointestinal disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG00119 affected533 at risk EG0021 affected14 at risk EG003
Haemorrhoids	Gastrointestinal disorders	15.0	Systematic Assessment	EG00019 affected551 at risk EG00112 affected533 at risk EG0021 affected14 at risk EG003
Mouth ulceration	Gastrointestinal disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG00133 affected533 at risk EG0021 affected14 at risk EG003
Nausea	Gastrointestinal disorders	15.0	Systematic Assessment	EG000276 affected551 at risk EG001325 affected533 at risk EG0024 affected14 at risk EG003
Sensitivity of teeth	Gastrointestinal disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Stomatitis	Gastrointestinal disorders	15.0	Systematic Assessment	EG00011 affected551 at risk EG00155 affected533 at risk EG0020 affected14 at risk EG003
Vomiting	Gastrointestinal disorders	15.0	Systematic Assessment	EG000126 affected551 at risk EG001145 affected533 at risk EG0022 affected14 at risk EG003
Asthenia	General disorders	15.0	Systematic Assessment	EG00043 affected551 at risk EG00187 affected533 at risk EG0022 affected14 at risk EG003
Chest pain	General disorders	15.0	Systematic Assessment	EG00046 affected551 at risk EG00147 affected533 at risk EG0020 affected14 at risk EG003
Chills	General disorders	15.0	Systematic Assessment	EG00047 affected551 at risk EG001179 affected533 at risk EG0023 affected14 at risk EG003
Fatigue	General disorders	15.0	Systematic Assessment	EG000214 affected551 at risk EG001354 affected533 at risk EG0027 affected14 at risk EG003
Influenza like illness	General disorders	15.0	Systematic Assessment	EG00038 affected551 at risk EG00185 affected533 at risk EG0023 affected14 at risk EG003
Local swelling	General disorders	15.0	Systematic Assessment	EG0006 affected551 at risk EG0011 affected533 at risk EG0022 affected14 at risk EG003
Malaise	General disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG00141 affected533 at risk EG0020 affected14 at risk EG003
Mucosal inflammation	General disorders	15.0	Systematic Assessment	EG0006 affected551 at risk EG00155 affected533 at risk EG0020 affected14 at risk EG003
Oedema	General disorders	15.0	Systematic Assessment	EG00046 affected551 at risk EG0016 affected533 at risk EG0020 affected14 at risk EG003
Oedema peripheral	General disorders	15.0	Systematic Assessment	EG000134 affected551 at risk EG00131 affected533 at risk EG0020 affected14 at risk EG003
Pain	General disorders	15.0	Systematic Assessment	EG00029 affected551 at risk EG00152 affected533 at risk EG0020 affected14 at risk EG003
Pyrexia	General disorders	15.0	Systematic Assessment	EG00091 affected551 at risk EG001217 affected533 at risk EG0023 affected14 at risk EG003
Cholestasis	Hepatobiliary disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0021 affected14 at risk EG003
Hepatotoxicity	Hepatobiliary disorders	15.0	Systematic Assessment	EG0005 affected551 at risk EG00115 affected533 at risk EG0021 affected14 at risk EG003
Bronchitis	Infections and infestations	15.0	Systematic Assessment	EG00054 affected551 at risk EG00140 affected533 at risk EG0020 affected14 at risk EG003
Cystitis	Infections and infestations	15.0	Systematic Assessment	EG00013 affected551 at risk EG0017 affected533 at risk EG0021 affected14 at risk EG003
Gastroenteritis	Infections and infestations	15.0	Systematic Assessment	EG00035 affected551 at risk EG0019 affected533 at risk EG0020 affected14 at risk EG003
Influenza	Infections and infestations	15.0	Systematic Assessment	EG00077 affected551 at risk EG00133 affected533 at risk EG0020 affected14 at risk EG003
Nasopharyngitis	Infections and infestations	15.0	Systematic Assessment	EG000167 affected551 at risk EG00147 affected533 at risk EG0022 affected14 at risk EG003
Pharyngitis	Infections and infestations	15.0	Systematic Assessment	EG00023 affected551 at risk EG00124 affected533 at risk EG0021 affected14 at risk EG003
Rhinitis	Infections and infestations	15.0	Systematic Assessment	EG00042 affected551 at risk EG00118 affected533 at risk EG0020 affected14 at risk EG003
Sinusitis	Infections and infestations	15.0	Systematic Assessment	EG00063 affected551 at risk EG00132 affected533 at risk EG0022 affected14 at risk EG003
Upper respiratory tract infection	Infections and infestations	15.0	Systematic Assessment	EG000114 affected551 at risk EG00145 affected533 at risk EG0020 affected14 at risk EG003
Urinary tract infection	Infections and infestations	15.0	Systematic Assessment	EG00036 affected551 at risk EG00131 affected533 at risk EG0020 affected14 at risk EG003
Animal bite	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0021 affected14 at risk EG003
Contusion	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG00030 affected551 at risk EG00115 affected533 at risk EG0020 affected14 at risk EG003
Muscle injury	Injury, poisoning and procedural complications	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Alanine aminotransferase abnormal	Investigations	15.0	Systematic Assessment	EG0001 affected551 at risk EG0013 affected533 at risk EG0021 affected14 at risk EG003
Alanine aminotransferase increased	Investigations	15.0	Systematic Assessment	EG00024 affected551 at risk EG00131 affected533 at risk EG0021 affected14 at risk EG003
Haemoglobin decreased	Investigations	15.0	Systematic Assessment	EG00011 affected551 at risk EG0019 affected533 at risk EG0021 affected14 at risk EG003
Platelet count decreased	Investigations	15.0	Systematic Assessment	EG0004 affected551 at risk EG0018 affected533 at risk EG0021 affected14 at risk EG003
Weight decreased	Investigations	15.0	Systematic Assessment	EG00026 affected551 at risk EG00191 affected533 at risk EG0021 affected14 at risk EG003
Weight increased	Investigations	15.0	Systematic Assessment	EG00086 affected551 at risk EG00114 affected533 at risk EG0021 affected14 at risk EG003
White blood cell count increased	Investigations	15.0	Systematic Assessment	EG0003 affected551 at risk EG0018 affected533 at risk EG0021 affected14 at risk EG003
Cachexia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG00053 affected551 at risk EG001207 affected533 at risk EG0022 affected14 at risk EG003
Dehydration	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG00111 affected533 at risk EG0021 affected14 at risk EG003
Fluid retention	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG00029 affected551 at risk EG0013 affected533 at risk EG0020 affected14 at risk EG003
Hypokalaemia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG00037 affected551 at risk EG00112 affected533 at risk EG0020 affected14 at risk EG003
Polydipsia	Metabolism and nutrition disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG000173 affected551 at risk EG001199 affected533 at risk EG0023 affected14 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG000137 affected551 at risk EG001105 affected533 at risk EG0022 affected14 at risk EG003
Bone pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG00058 affected551 at risk EG00178 affected533 at risk EG0022 affected14 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG000272 affected551 at risk EG00163 affected533 at risk EG0021 affected14 at risk EG003
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG00034 affected551 at risk EG00130 affected533 at risk EG0021 affected14 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG000131 affected551 at risk EG001200 affected533 at risk EG0024 affected14 at risk EG003
Neck pain	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG00026 affected551 at risk EG00111 affected533 at risk EG0021 affected14 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	15.0	Systematic Assessment	EG000107 affected551 at risk EG00189 affected533 at risk EG0020 affected14 at risk EG003
Chronic myeloid leukaemia	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0002 affected551 at risk EG0010 affected533 at risk EG0021 affected14 at risk EG003
Neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Systematic Assessment	EG0001 affected551 at risk EG0011 affected533 at risk EG0021 affected14 at risk EG003
Ageusia	Nervous system disorders	15.0	Systematic Assessment	EG0001 affected551 at risk EG0014 affected533 at risk EG0021 affected14 at risk EG003
Amnesia	Nervous system disorders	15.0	Systematic Assessment	EG00010 affected551 at risk EG00135 affected533 at risk EG0020 affected14 at risk EG003
Disturbance in attention	Nervous system disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG00137 affected533 at risk EG0021 affected14 at risk EG003
Dizziness	Nervous system disorders	15.0	Systematic Assessment	EG000105 affected551 at risk EG001124 affected533 at risk EG0023 affected14 at risk EG003
Dizziness postural	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0013 affected533 at risk EG0021 affected14 at risk EG003
Dysarthria	Nervous system disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0012 affected533 at risk EG0021 affected14 at risk EG003
Dysgeusia	Nervous system disorders	15.0	Systematic Assessment	EG00017 affected551 at risk EG00148 affected533 at risk EG0021 affected14 at risk EG003
Headache	Nervous system disorders	15.0	Systematic Assessment	EG000205 affected551 at risk EG001231 affected533 at risk EG0022 affected14 at risk EG003
Lethargy	Nervous system disorders	15.0	Systematic Assessment	EG00011 affected551 at risk EG00136 affected533 at risk EG0020 affected14 at risk EG003
Memory impairment	Nervous system disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0019 affected533 at risk EG0021 affected14 at risk EG003
Migraine	Nervous system disorders	15.0	Systematic Assessment	EG00014 affected551 at risk EG0016 affected533 at risk EG0021 affected14 at risk EG003
Neuropathy peripheral	Nervous system disorders	15.0	Systematic Assessment	EG00014 affected551 at risk EG00124 affected533 at risk EG0021 affected14 at risk EG003
Paraesthesia	Nervous system disorders	15.0	Systematic Assessment	EG00050 affected551 at risk EG00139 affected533 at risk EG0020 affected14 at risk EG003
Peripheral sensory neuropathy	Nervous system disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0013 affected533 at risk EG0021 affected14 at risk EG003
Anxiety	Psychiatric disorders	15.0	Systematic Assessment	EG00052 affected551 at risk EG00160 affected533 at risk EG0023 affected14 at risk EG003
Depression	Psychiatric disorders	15.0	Systematic Assessment	EG00084 affected551 at risk EG001186 affected533 at risk EG0023 affected14 at risk EG003
Disorientation	Psychiatric disorders	15.0	Systematic Assessment	EG0000 affected551 at risk EG0011 affected533 at risk EG0021 affected14 at risk EG003
Insomnia	Psychiatric disorders	15.0	Systematic Assessment	EG00083 affected551 at risk EG00199 affected533 at risk EG0020 affected14 at risk EG003
Mood altered	Psychiatric disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG00122 affected533 at risk EG0021 affected14 at risk EG003
Nervousness	Psychiatric disorders	15.0	Systematic Assessment	EG0009 affected551 at risk EG0017 affected533 at risk EG0021 affected14 at risk EG003
Dysuria	Renal and urinary disorders	15.0	Systematic Assessment	EG00011 affected551 at risk EG00115 affected533 at risk EG0022 affected14 at risk EG003
Polyuria	Renal and urinary disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0012 affected533 at risk EG0021 affected14 at risk EG003
Prostatitis	Reproductive system and breast disorders	15.0	Systematic Assessment	EG0003 affected551 at risk EG0011 affected533 at risk EG0021 affected14 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG000111 affected551 at risk EG001122 affected533 at risk EG0024 affected14 at risk EG003
Dry throat	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0002 affected551 at risk EG0017 affected533 at risk EG0021 affected14 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG00050 affected551 at risk EG00175 affected533 at risk EG0021 affected14 at risk EG003
Epistaxis	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG00020 affected551 at risk EG00142 affected533 at risk EG0020 affected14 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG000100 affected551 at risk EG00161 affected533 at risk EG0023 affected14 at risk EG003
Productive cough	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG00015 affected551 at risk EG00120 affected533 at risk EG0021 affected14 at risk EG003
Pulmonary congestion	Respiratory, thoracic and mediastinal disorders	15.0	Systematic Assessment	EG0007 affected551 at risk EG0015 affected533 at risk EG0021 affected14 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG00030 affected551 at risk EG001125 affected533 at risk EG0022 affected14 at risk EG003
Dry skin	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG00046 affected551 at risk EG00144 affected533 at risk EG0021 affected14 at risk EG003
Erythema	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG00040 affected551 at risk EG00123 affected533 at risk EG0020 affected14 at risk EG003
Hyperhidrosis	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG00033 affected551 at risk EG00179 affected533 at risk EG0020 affected14 at risk EG003
Night sweats	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG00055 affected551 at risk EG00184 affected533 at risk EG0022 affected14 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG00053 affected551 at risk EG00163 affected533 at risk EG0020 affected14 at risk EG003
Rash	Skin and subcutaneous tissue disorders	15.0	Systematic Assessment	EG000154 affected551 at risk EG00191 affected533 at risk EG0020 affected14 at risk EG003
Haematoma	Vascular disorders	15.0	Systematic Assessment	EG0009 affected551 at risk EG0018 affected533 at risk EG0022 affected14 at risk EG003
Hypertension	Vascular disorders	15.0	Systematic Assessment	EG00050 affected551 at risk EG00116 affected533 at risk EG0020 affected14 at risk EG003
Peripheral coldness	Vascular disorders	15.0	Systematic Assessment	EG0004 affected551 at risk EG0017 affected533 at risk EG0021 affected14 at risk EG003

Ancestor Terms

ID	Term
D001549	Benzamides
D000577	Amides
D009930	Organic Chemicals
D001565	Benzoates
D000146	Acids, Carbocyclic
D002264	Carboxylic Acids
D001555	Benzene Derivatives
D006841	Hydrocarbons, Aromatic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D010879	Piperazines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D011743	Pyrimidines
D007370	Interferon Type I
D007372	Interferons
D016207	Cytokines
D036341	Intercellular Signaling Peptides and Proteins
D010455	Peptides
D000602	Amino Acids, Peptides, and Proteins
D011506	Proteins
D001685	Biological Factors
D003562	Cytidine
D011741	Pyrimidine Nucleosides
D001087	Arabinonucleosides
D009705	Nucleosides
D009706	Nucleic Acids, Nucleotides, and Nucleosides

ID	Term
D007951	Leukemia, Myeloid
D007938	Leukemia
D009370	Neoplasms by Histologic Type
D009369	Neoplasms
D009196	Myeloproliferative Disorders
D001855	Bone Marrow Diseases
D006402	Hematologic Diseases
D006425	Hemic and Lymphatic Diseases
D002908	Chronic Disease
D020969	Disease Attributes
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms

ID	Term
D000068877	Imatinib Mesylate
D016898	Interferon-alpha
D003561	Cytarabine